

ACTA MEDICINAE 6/2013 Kompletní literatura

PRAKTICKÝ LÉKAŘ

- 2 **Nevyužité možnosti primární péče**
doc. MUDr. Svatopluk Býma, CSc. předseda SVL ČLS JEP, LF UK v Hradci Králové
MUDr. Václav Šmatlák předseda SPL ČR, VPL Praha
- 2 **Doporučený postup péče o pacienty s diabetes mellitus pro praktické lékaře**
MUDr. Igor Karen koordinátor a autor Doporučeného postupu, praktický lékař pro dospělé, Benátky nad Jizerou
- 2 **Národní imunizační program**
prof. MUDr. Roman Prymula, CSc., Ph.D. FN Hradec Králové a Česká vakcinologická společnost JEP
- 3 **Nové poznatky o účinnosti HPV vakcinace**
MUDr. Borek Sehnal Gynekologicko-porodnická klinika, Nemocnice Na Bulovce a 1. LF UK Praha
- 3 **Úloha praktického pediatra v očkování (nejen proti pneumokokům)**
MUDr. Martina Spaziererová PLDD, Kladno
- 4 **Antihypertenzní léčba v primární a sekundární prevenci cévních mozkových příhod**
prof. MUDr. Jan Filipovský, CSc. II. interní klinika LF UK a FN Plzeň
- 4 **Broncho-Vaxom a jeho přínos pro klinickou praxi**
MUDr. Ester Seberová RESPIRAL, s. r. o., Plzeň
- 4 **Vápník a vitamin D v prevenci a terapii osteoporózy**
MUDr. Jan Rosa Osteocentrum Mediscan Group, Euromedic, Praha
- 6 **Vitamin D ve stáří**
MUDr. Jana Čepová, Ph.D., MBA | Ing. Eva Klapková, Ph.D. |
Ing. Marta Pechová | Ing. Eliška Glasová | prof. MUDr. Richard Průša, CSc.
Ústav lékařské chemie a klinické biochemie, 2. LF UK a FN v Motole, Praha
- 7 **Fixní kombinace v léčbě hypertenze**
MUDr. Eva Kociánová I. Interní klinika – kardiologická, Fakultní Nemocnice Olomouc
- 7 **Léčba hypertenze v primární péči**
MUDr. Zdeněk Hamouz Praktický lékař, SPL ČR, ČIMS, o. p. s.
- 8 **Akutní infekce dýchacích cest, jejich diagnostika a léčba z pohledu ORL lékaře**
MUDr. Petra Bruthansová | MUDr. Pavol Jablonický
Klinika otorinolaryngologie a chirurgie hlavy a krku 1. LF UK a FN Motol, Praha
- 8 **Klarithromycin v léčbě atypických pneumonií**
MUDr. Jiří Slíva, Ph.D. Ústavy farmakologie 2. a 3. LF UK, Praha

Nevyužití možnosti primární péče

doc. MUDr. Svatopluk Býma, CSc. předseda SVL ČLS JEP, LF UK v Hradci Králové

MUDr. Václav Šmatlák předseda SPL ČR, VPL Praha

- 1 *Vývoj zdravotnictví České republiky po roce 1989*. Online, cit. 18. 1. 2013, dostupné na www.uzis.cz.
- 2 *Zdravotnická ročenka České republiky 2011*. Online, cit. 18. 1. 2013, dostupné na www.uzis.cz.

Doporučený postup péče o pacienty s diabetes mellitus pro praktické lékaře

MUDr. Igor Karen koordinátor a autor Doporučeného postupu, praktický lékař pro dospělé, Benátky nad Jizerou

- 1 Karen, I. – Svačina, Š. – Škrha, J.: *Diabetes mellitus*. Doporučené postupy SVL ČLS JEP, 2013.
- 2 Karen, I. – Kvapil, M. – Škrha, J.: *Diabetes mellitus*. Doporučené postupy SVL ČLS JEP, 2009.
- 3 Výbor ČDS ČLS JEP: *Standardy péče o diabetes mellitus 2. typu*. DMEV, 2011.
- 4 Karen, I. – Svačina, Š.: *Diabetes mellitus v primární péči*. Axonite, 2011.
- 5 *Doporučené postupy České diabetologické společnosti*: www.diab.cz.
- 6 Karen, I. – Widimský, J.: *Arteriální hypertenze*. Doporučené postupy SVL ČLS JEP, 2008.
- 7 Herber, O. – Býma, S. – Karen, I.: *Dyslipidemie*. *Prevence KVO*. Doporučené postupy SVL ČLS JEP, 2004.
- 8 Karen, I. – Souček, M.: *Metabolický syndrom – diagnostika a léčba*. Doporučené postupy SVL ČLS JEP, 2007.
- 9 www.svl.cz.
- 10 Rybka, J., et al.: *Ambulantní péče o diabetika*, 2000.
- 11 **European Diabetes Policy Group**: *Guidelines for diabetes care. A desktop guide to type 2 diabetes mellitus*. IDF European region. Německo, Walter Wirtz Druck Verlag, srpen 1999.
- 12 Svačina, Š.: *Prevence diabetu a jeho komplikací*. Praha, Triton, 2008, s. 152.
- 13 Škrha, J.: Farmakoterapie diabetes mellitus. In: Marek, J., et al.: *Farmakoterapie nemocí vnitřních*. Praha, Grada, 2010, 4, s. 395–407.
- 14 Svačina, Š., et al.: *Klinická dietologie*. Grada, 2008, s. 381.
- 15 Kvapil, M. – Adamčíková, A. – Anděl, M. – Olšovský, A. – Pelikánová, T. – Račická, E. – Rušavý, Z.: *Diabetologie, metabolismus, endokrinologie, výživa... Konsensus k léčbě inzulinovými analogy*.
- 16 **Perušičová, J.**: Perorální antidiabetika. In: *Trendy soudobé diabetologie*. Praha, Galén, 1998, svazek 1.
- 17 **Perušičová, J.**: *Desatera léčby perorálními antidiabetiky*. Praha, Triton, 2004.
- 18 **Pelikánová, T. – Bartoš, V., et al.**: *Praktická diabetologie*. 5. rozšířené vydání. Praha, Maxdorf, 2011, s. 742.
- 19 **Olšovský, J. – Žáčková, V.**: Diabetologie. In: Zicha, J., et al.: *Rukověť základů praktické interny*. MU v Brně, 2001, s. 188–196.
- 20 **Keen, H.**: Therapeutic objectives and their practical achievement in type 2 diabetes. *Journal of Diabetes and Its Complications*, 2000, 14, s. 180–184.
- 21 **Morris, A. D.**: The reality of type 2 diabetes treatment today. *International Journal of Clinical Practice*, 2001, 121, s. 32–35.
- 22 **Pickup, J. C. – Williams, G.**: *Textbook of diabetes. Management of non-insulin-dependent diabetes mellitus*. Second Edition. Blackwell Science, 1998, 37, s. 8.
- 23 **Doležalová, K. – Býma, S. – Fried, M. – Svačina, Š., et al.**: *Bariatrická chirurgie a primární péče*. Axonite, 2012.
- 24 **Sinagra, D.**: Effects of insulin-oral hypoglycemic agents combined therapy in outpatients with type 2 diabetes. *European-Review-for-medical-and-Pharmacological-Sciences*, 1998, 2, s. 175–179.
- 25 **Alberti, K. G. M. M.**: Treating type 2 diabetes—today's targets, tomorrow's goals. *Abstract book 36th Congress EASD*. Jeruzalém, 2000, s. 6–7.
- 26 *Consensus statement for the management of Patients with type 2 diabetes mellitus in the Central, Eastern and Southern European region*, listopad 1999 – leden 2000, Budapešť.
- 27 **Nathan, D. M. – Buse, J. B. – Davidson, M. B. – Ferrannini, E. – Holman, R. R. – Sherwin, R. – Zinman, B.**: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. *Diab Care*, 2008, 31.

Národní imunizační program

prof. MUDr. Roman Prymula, CSc., Ph.D. FN Hradec Králové a Česká vakcinologická společnost JEP

- 1 **Dye, C.**: A Booster for tuberculosis vaccines. *JAMA*, 2004, 291, s. 2127–2128.
- 2 Vyhláška č. 537 ze dne 29. listopadu 2006 *O očkování proti infekčním nemocem*.
- 3 Vyhláška č. 65/2009 Sb. ze dne 25. února 2009, kterou se mění vyhláška č. 537/2006 Sb., o očkování proti infekčním nemocem.
- 4 Zákon č. 362/2009 Sb. ze dne 5. října 2009, kterým se mění některé zákony v souvislosti s návrhem zákona o státním rozpočtu České republiky na rok 2010.
- 5 Vyhláška č. 299/2010 Sb. ze dne 25. října 2010, kterou se mění vyhláška č. 537/2006 Sb., o očkování proti infekčním nemocem, ve znění pozdějších předpisů.
- 6 Zákon č. 369/2011 Sb. ze dne 6. listopadu 2011, kterým se mění zákon č. 48/1997 Sb., o veřejném zdravotním pojištění a o změně a doplnění některých souvisejících zákonů, ve znění pozdějších předpisů, a některé další zákony (část týkající se očkování).
- 7 **Wolfson, L. J. – Strebel, P. M. – Gacic-Dobo, M. – Hoekstra, E. J. – McFarland, J. W. – Hersh, B. S.**: Measles Initiative: Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. *Lancet*, 2007, 369, s. 191–200.
- 8 **World Health Organisation (WHO)**: Pertussis vaccines – WHO Position Paper. *Wkly Epidemiol Rec*, 2005, 80, s. 31–39.

Nové poznatky o účinnosti HPV vakcinace

MUDr. Borek Sehnal Gynekologicko-porodnická klinika, Nemocnice Na Bulovce a 1. LF UK Praha

- 1 De Vuyst, H. – Clifford, G. M. – Nascimento, M. C., et al.: Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. *Int J Cancer*, 2009, 124, s. 1626–1636.
- 2 Parkin, D. M. – Bray, F.: The burden of HPV-related cancers. *Vaccine*, 2006, 24 (dopl. 3), s. 11–25.
- 3 Tjalma, W. A. – Fiander, A. – Reich, O., et al.: Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. *Int J Cancer*, 2013, 132, s. 854–867.
- 4 Weiss, P. – Zvěřina, J.: *Sexuální chování obyvatel v ČR*. Praha, Dema, 2003, s. 28–32.
- 5 *Silgard SPC* (Summary of Product Characteristics, Souhrn údajů o přípravku). Dostupné z: <http://www.medicines.org.uk/emc/medicine/19016/SPC/gardasil/>, vyhledáno 16. 7. 2013.
- 6 *Cervarix SPC* (Summary of Product Characteristics, Souhrn údajů o přípravku). Dostupné z: <http://www.medicines.org.uk/emc/medicine/20204/SPC/cervarix/>, vyhledáno 16. 7. 2013.
- 7 Paavonen, J. – Naud, P. – Salmerón, J., et al.: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. *Lancet*, 2009, 374, s. 301–314.
- 8 Villa, L. L. – Costa, R. L. – Petta, C. A., et al.: High sustained efficacy of a prophylactic quadrivalent human papillomavirus typy 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. *Br J Cancer*, 2009, 95, s. 1459–1466.
- 9 Muñoz, N. – Kjaer, S. K. – Sigurdsson, K., et al.: Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. *J Natl Cancer Inst*, 2010, 102, s. 1–15.
- 10 Romanowski, B. – de Borja, P. C. – Naud, P. S., et al.: Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. *Lancet*, 2009, 374, s. 1975–1985.
- 11 Herrero, R.: Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. *J Infect Dis*, 2009, 199, s. 919–922.
- 12 Wentzensen, N. – Schiffman, M. – Dunn, T., et al.: Multiple human papillomavirus genotype infection in cervical cancer progression in study to understand cervical cancer early endpoints and determinants. *Int J Cancer*, 2009, 125, s. 2151–2158.
- 13 Rob, L.: Workshop *Novinky v cervikální patologii*, Konference Nemocničních gynekologů a porodníků, 30. 9.–2. 10. 2011, Praha, přednáška.
- 14 Weinberger, P. M. – Yu, Z. – Haffty, B. G., et al.: Molecular classification identifies subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. *J Clin Oncol*, 2006, 24, s. 736–747.
- 15 Klozar, J. – Tachezy, R. – Rotnaglova, E., et al.: Human papillomavirus in head and neck tumors: epidemiological, molecular and clinical aspects. *Wien Med Wochenschr*, 2010, 160, s. 305–309.
- 16 Näsman, A. – Attner, P. – Hammarstedt, L., et al.: Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? *Int J Cancer*, 2009, 125, s. 362–366.
- 17 Kašpírková, J. – Ondič, O. – Černá, K. – Skálová, A.: Možnosti průkazu biologicky relevantní papilomavírové infekce u maligních nádorů hlavy a krku v diagnostické patologii. *Cesk Patol*, 2013, 49, s. 29–34.
- 18 Spitzer, M.: Human papillomavirus: epidemiology, natural history, and clinical sequelae. *OBG Management*, 2006, 18, s. S5–S10.

Úloha praktického pediatra v očkování (nejen proti pneumokokům)

MUDr. Martina Spaziererová PLDD, Kladno

- 1 Kynčl, J.: *Chřipka – neviditelný nepřítel: zvýšíme proočkovanosť u indikovaných pacientů na 75 %?* Přednáška na Hradeckých vakcinologických dnech, říjen 2011.
- 2 www.pmfhk.cz/WWW/HVD_2011/Kyncl_Chripka.pdf, vyhledáno 2. 9. 2013.
- 3 www.florence.cz/odborne-clanky/archiv-akcent-vzp/2012/3/ockovani-proti-rotavirum/, vyhledáno 2. 9. 2013.
- 4 <http://pozorkliste.cz/cr-ma-nejvice-pripadu-klistove-encefality>, vyhledáno 2. 9. 2013.
- 5 Chlíbek, J.: *Nepovinná očkování pohledem vakcinologa*. Přednáška na semináři OSPDL na téma očkování, květen 2013.
- 6 Vyhláška č. 439/2000 Sb., o očkování proti infekčním nemocem
- 7 Hsu, K. – Pelton, S. – Karumuri, S. – Heisey-Grove, D. – Klein, J.: Population-based surveillance for childhood invasive pneumococcal disease in the Era of conjugate vaccine. *Pediatr Infect Dis J*, 2005, 24, 1, s. 17–23.
- 8 Blafli, S. – Shinefield, H. – Fireman, B., et al., and the Northern California Kaiser Permanente Vaccine Study Center Group. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. *Pediatr Infect Dis J*, 2000, 19, s. 187–195.
- 9 Zákon č. 48/1997 Sb., o všeobecném zdravotním pojištění.
- 10 Kosina, P. – Štochl, J.: Význam desetivalentní konjugované vakcíny Synflorix™ (PCV10) v kontextu nových účinnostních dat. *Pediatr praxi*, 2013, 14, 2, s. 141–142.
- 11 Palmu, A. A., et al.: Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. *The Lancet*, [http://dx.doi.org/10.1016/S0140-6736\(12\)61854-6](http://dx.doi.org/10.1016/S0140-6736(12)61854-6).
- 12 Kozáková, J., et al.: Invazivní pneumokokové onemocnění v České republice v roce 2012. *Zprávy CEM*, 2013, 22, 3, s. 97–104.

Antihypertenzní léčba v primární a sekundární prevenci cévních mozkových příhod

prof. MUDr. Jan Filipovský, CSc. II. interní klinika LF UK a FN Plzeň

- 1 **Chalmers, J. – Beilin, L. – Mancia, G., et al.:** International Society of Hypertension: statements on blood pressure and stroke. *J Hypertension*, 2003, 21, s. 649–650.
- 2 **Wright, J. M. – Musini, V. M.:** First-line drugs for hypertension. Cochrane Database of Systematic Reviews, 2009, 3, Art. No.: CD001841, doi: 10.1002/14651858.CD001841, pub 2.
- 3 **Beckett, N. S. – Peters, R. – Fletcher, A. E., et al.:** Treatment of hypertension in patients 80 years of age or older. *N Engl J Med*, 2008, 358, s. 1–12.
- 4 **PROGRESS Collaborative Group.** Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. *Lancet*, 2001, 358, s. 1033–1041.
- 5 **Arima, H. – Chalmers, J. – Woodward, M., et al.:** Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. *J Hypertension*, 2006, 24, s. 1201–1208.
- 6 **Yusuf, S. – Diener, H. C. – Sacco, R. L., et al.:** Telmisartan to prevent recurrent stroke and cardiovascular events. *NEJM*, 2008, 359, s. 1225–1237.
- 7 **Sandset, E. C. – Bath, P. M. – Bosen, G., et al.:** The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. *Lancet*, 2011, 377, s. 741–750.
- 8 **Filipovský, J. – Widimský, J. Jr. – Ceral, J. – Cífková, R. – Horký, K. – Linhart, A. – Monhart, V. – Rosolová, H. – Seidlerová, J. – Souček, M. – Špinar, J. – Vitovec, J. – Widimský, J.:** Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. *Vnitř Léč*, 2012, 58, s. 785–801.

Broncho-Vaxom a jeho přínos pro klinickou praxi

MUDr. Ester Seberová RESPIRAL, s. r. o., Plzeň

- 1 **World Health Organisation:** Acute respiratory infections: the forgotten pandemic. *Bull WHO*, 1998, 76, s. 101–103.
- 2 **Bartůňková, J. – Šedivá, A. – Janda, A.:** *Imunodeficiency*. 2. přepracované a doplněné vydání. Grada Publishing, Praha, 2007.
- 3 **De Baets, F., et al.:** IgG subclass deficiency in children with recurrent bronchitis. *Eur J Pediatr*, 1992, 151, s. 274–278.
- 4 **David, J. R. – Rosen, F. S.:** Deficiencies in immunoglobulins and cell-mediated immunity, Chapter IX. In: *Scientific American Medicine*, New York NY, SAM-CD 2000.
- 5 **Turzíková, J. – Petrů, V.:** Opakované respirační infekce. In: *Dětská alergologie*. Mladá fronta, Praha, 2012, s. 431–447.
- 6 **Schaad, U. B., et al.:** Immunostimulation with OM-85 in children with recurrent infection of the upper respiratory tract. *Chest*, 2002, 122, s. 2042–2049.
- 7 **Luotonen, M. – Ujati, M., et al.:** Recurrent otitis media during infancy and linguistic skills at the age of nine years. *Pediatr Infect Dis J*, 1996, 15, s. 854–858.
- 8 **Bacharier, L. B., et al.:** European pediatric asthma group: Diagnosis and treatment of asthma in childhood: a PRACTALL konsensus report. *Allergy*, 2008, 63, s. 5–34.
- 9 **GOLD:** Global Strategy for Diagnosis, Management and Prevention of COPD, 2011.
- 10 **Wilson, R.:** A vicious circle hypothesis operating during infective exacerbations of chronic bronchitis. *Monaldi Arch Chest Dis*, 1994, 49, s. 159–164.
- 11 **Wilson, R.:** Infections of the airways. *Curr Opin Infect Dis*, 1991, 4, s. 166–175.
- 12 **Murphy, T. F. – Sethi, S.:** State of the art. Bacterial infection in chronic obstructive pulmonary disease. *Ann Rev Respir Dis*, 1992, 146, s. 1067–1083.
- 13 **Špičák, V. – Petrů, V.:** Imunoterapie a imunomodulace. In: *Dětská alergologie*, Mladá fronta, Praha, 2012, s. 142–146.
- 14 **Mestecky, J., et al.:** Selective induction of an imine response in human external secretions by ingestion of bacterial antigen. *J Clin Invest*, 1978, 61, s. 731–737.
- 15 **Emmerich, B., et al.:** Local immunity in patients with chronic bronchitis and the effects of a bacterial extract, Broncho-Vaxom on T-lymphocytes, macrophages, gamma-interferon and secretory immunoglobulin A in bronchoalveolar lavage fluid and other variables. *Respiration*, 1990, 57, s. 90–99.
- 16 **SPC Broncho-Vaxom.**
- 17 **Collet, J. P., et al.:** Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 1997, 156, s. 1719–1724.
- 18 **Marit, M. – Chiavaroli, C.:** Mechanism of action and therapeutic efficacy of the biotechnology-derived immunostimulating extract OM-85 in respiratory tract infections. *Int J Biotechnology*, 2007, 9, s. 344–359.
- 19 **Schaad, U. B., et al.:** Immunostimulation with OM-85 in children with recurrent infections of the upper respiratory tract. *Chest*, 2002, 122, s. 2042–2049.
- 20 **Orcel, B., et al.:** Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. *Eur Respir J*, 1994, 7, s. 446–452.

Vápník a vitamin D v prevenci a terapii osteoporózy

MUDr. Jan Rosa Osteocentrum Mediscan Group, Euromedic, Praha

- 1 **Holick, M. F.:** Vitamin D deficiency. *N Engl J Med*, 2007, 357, s. 266–281.
- 2 **Holick, M. F.:** Resurrection of vitamin D deficiency and rickets. *J Clin Invest*, 2006, 116, s. 2062–2072.
- 3 **Trang, H. M. – Cole, D. E. C. – Rubin, L. A., et al.:** Evidence that vitamin D₃ increases serum 25-hydroxyvitamin D more efficiently than does vitamin D₂. *Am J Clin Nut*, 1998, 68, s. 854–858.
- 4 **Armas, L. A. G. – Hollis, B. – Heaney, R. P.:** Vitamin D₂ is much less effective than vitamin D₃ in humans. *J Clin Endocrinol Metab*, 2004, 89, s. 5387–5391.
- 5 **Holick, M. F. – Biancuzzo, R. M. – Chen, T. C., et al.:** Vitamin D₂ is as

- effective as vitamin D₃ in maintaining circulating concentrations of 25-hydroxyvitamin D. *J Clin Endocrinol Metab*, 2008, 93, s. 677–681.
- 6 **Institute of Medicine, Food and Nutrition Board:** *Dietary Reference Intakes for Calcium and Vitamin D*. Washington, DC, National Academy Press, 2010.
 - 7 **Cranney, C. – Horsely, T. – O'Donnell, S., et al.:** *Effectiveness and safety of vitamin D. Evidence Report/Technology Assessment No. 158 prepared by the University of Ottawa Evidence-based Practice Center under Contract No. 290-02.0021*. AHRQ Publication No. 07-E013.
 - 8 **Nordin, B. E. – Heaney, R. P.:** Calcium supplementation of the diet: Justified by present evidence. *BMJ*, 1990, 300, s. 1056–1060.
 - 9 **Straub, D. A.:** Calcium supplementation in clinical practice: a review of forms, doses, and indications. *Nutr Clin Pract*, 2007, 22, s. 286–296.
 - 10 **Lafage-Proust, M. H. – Lieben, L. – Carmeliet, G., et al.:** High bone turnover persisting after vitamin D repletion: beware of calcium deficiency. *Osteoporos Int*, 2013, doi: 10.1007/s00198-013-2273-2281.
 - 11 **Durazo-Arvizu, R. A. – Dawson-Hughes, B. – Sempos, C. T., et al.:** Three-phase model harmonizes estimates of the maximal suppression of parathyroid hormone by 25-hydroxyvitamin D in persons 65 years of age and older. *J Nutr*, 2010, 140, s. 595–599.
 - 12 **Sai, A. J. – Walters, R. W. – Fang, X., et al.:** Relationship between vitamin D, parathyroid hormone, and bone health. *J Clin Endocrinol Metab*, 2011, 96, s. E436–E446.
 - 13 **Priemel, M. – Von Demarshaus, C. – Klatte, T. O., et al.:** Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. *J Bone Miner Res*, 2010, 25, s. 305–312.
 - 14 **Chapuy, M. C. – Preziosi, P. – Maamer, M., et al.:** Prevalence of vitamin D insufficiency in an adult normal population. *Osteoporos Int*, 1997, 7, s. 439–443.
 - 15 **Steingrimsdottir, L. – Gunnarsson, O. – Indridason, S. – Franzson, L. – Sigurdsson, G.:** Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. *JAMA*, 2005, 294, s. 2336–2341.
 - 16 **Thacher, T. D. – Clarke, B. L.:** Vitamin D Insufficiency. *Mayo Clin Proc*, 2011, 86, s. 50–60.
 - 17 **Rosen, C. J.:** Vitamin D insufficiency. *N Engl J Med*, 2011, 364, s. 248–254.
 - 18 **Glade, M. J.:** A 21st century evaluation of the safety of oral vitamin D. *Nutrition*, 2012, 28, s. 344–356.
 - 19 **Nordin, B. E. C.:** The effect of calcium supplementation on bone loss in 32 controlled trials in postmenopausal women. *Osteoporos Int*, 2009, 20, s. 2135–2143.
 - 20 **Nordin, B. E. C.:** Calcium and osteoporosis. *Nutrition*, 1997, 13, s. 664–686.
 - 21 **Dawson-Hughes, B. – Dallal, G. E. – Krall, E. A., et al.:** A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. *N Engl J Med*, 1990, 323, s. 878–883.
 - 22 **Reid, I. R. – Mason, B. – Horne, A., et al.:** Randomized controlled trial of calcium in healthy older women. *Am J Med*, 2006, 119, s. 777–785.
 - 23 **Seeman, E.:** Comment on review by Nordin: "The effect of calcium supplementation on bone loss in 32 controlled trials in postmenopausal women". *Osteoporos Int*, 2009, 20, s. 2145–2146.
 - 24 **Seeman, E.:** Evidence that calcium supplements reduce fracture risk is lacking. *Clin J Am Soc Nephrol*, 2010, 5, s. S3–S11.
 - 25 **Tang, B. M. – Eslick, G. D. – Nowson, C. – Smith, C. – Bensoussan, A.:** Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: A meta-analysis. *Lancet*, 2007, 370, s. 657–666.
 - 26 **Gordon, C. M. – Williams, A. L. – Feldman, H. A., et al.:** Treatment of hypovitaminosis D in infants and toddlers. *J Clin Endocrinol Metab*, 2008, 93, s. 2716–2721.
 - 27 **Bischoff-Ferrari, H. A. – Willett, W. C. – Wong, J. B., et al.:** Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. *JAMA*, 2005, 293, s. 2257–2264.
 - 28 **Bischoff-Ferrari, H. A. – Giovannucci, E. – Willett, W. C., et al.:** Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. *Am J Clin Nutr*, 2006, 84, s. 18–22.
 - 29 **Pfeifer, M. – Begerow, B. – Minne, H. W., et al.:** Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. *J Bone Miner Res*, 2000, 15, s. 1113–1118.
 - 30 **Pfeifer, M. – Begerow, B. – Minne, H. W., et al.:** Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. *Osteoporos Int*, 2009, 20, s. 315–322.
 - 31 **Broe, K. E. – Chen, T. C. – Weinberg, J., et al.:** A higher dose of vitamin D reduces the risk of falls in nursing home residents: a randomized, multiple-dose study. *J Am Geriatr Soc*, 2007, 55, s. 234–239.
 - 32 **Bischoff-Ferrari, H. A. – Willett, W. C. – Orav, E. J., et al.:** A pooled analysis of vitamin D dose requirements for fracture prevention. *N Engl J Med*, 2012, 367, s. 40–49.
 - 33 **The DIPART (vitamin D Individual Patient Analysis of Randomized Trials) Group:** Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. *BMJ*, 2010, 340, s. b5463.
 - 34 **Trivedi, D. P. – Doll, R. – Khaw, K. T.:** Effect of four monthly oral vitamin D₃ (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. *BMJ*, 2003, 326, s. 469–474.
 - 35 **Sanders, K. – Stuart, A. – Williamson, E., et al.:** Annual high-dose oral vitamin D for falls and fractures in elderly women: a randomised, double-blind, placebo-controlled study. *JAMA*, 2010, 303, s. 1815–1822.
 - 36 **Smith, H. – Anderson, F. – Raphael, H., et al.:** Effect of annual intramuscular vitamin D on fracture risk in elderly men and women—a population-based, randomized, double-blind, placebo-controlled trial. *Rheumatology*, 2007, 46, s. 1852–1857.
 - 37 **Dawson-Hughes, B. – Harris, S. S. – Krall, E. A. – Dallal, G. E.:** Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. *N Engl J Med*, 1997, 337, s. 670–676.
 - 38 **Bergman, G. J. D. – Fan, T. – McFetridge, J. T. – Sen, S. S.:** Efficacy of vitamin D₃ supplementation in preventing fractures in elderly women: A meta-analysis. *Current Medical Research & Opinion*, 2010, 26, s. 1193–1201.
 - 39 **Boonen, S. – Lips, P. – Bouillon, R. – Bischoff-Ferrari, H. A., et al.:** Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative meta-analysis of randomized controlled trials. *J Clin Endocrinol Metab*, 2007, 92, s. 1415–1423.
 - 40 **Ian, H. – de Boer, I. H. – Levin, G. – Robinson-Cohen, C., et al.:** Serum 25-hydroxyvitamin D concentration and risk for major clinical disease events in a community-based population of older adults: a cohort study. *Ann Intern Med*, 2012, 156, s. 627–634.
 - 41 **Chung, M. – Lee, J. – Terasawa, T. – Lau, J. – Trikalinos, T. A.:** Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. *Ann Intern Med*, 2011, 155, s. 827–838.
 - 42 **Cremers, S. – Papapoulos, S.:** Pharmacology of bisphosphonates. *Bone*, 2011, 49, s. 42–49.
 - 43 http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000595/WC500020940.pdf.
 - 44 http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000619/WC500024251.pdf.
 - 45 **Peter, R. – Mishra, V. – Fraser, W. D.:** Severe hypocalcaemia after being given intravenous bisphosphonate. *BMJ*, 2004, 328, s. 335–336.
 - 46 **Shapses, S. A. – Kendler, D. L. – Rondon, R., et al.:** Effect of alendronate and vitamin D₃ on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women. *J Bone Mineral Res*, 2011, 26, s. 1836–1844.
 - 47 **Barone, A. – Giusti, A. – Pioli, G., et al.:** Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response

- to alendronate in elderly women with osteoporosis: a randomized controlled trial. *J Am Geriatr Soc*, 2007, 55, s. 752–757.
- 48 **Antonucci, D. M. – Vittinghoff, E. – Palermo, L. – Black, D. M. – Sellmeyer, D. E.:** Vitamin D insufficiency does not affect response of bone mineral density to alendronate. *Osteoporos Int*, 2009, 20, s. 1259–1266.
 - 49 **Binkley, N. – Ringe, J. D. – Reed, J. I., et al.:** Alendronate/vitamin D370 mg/2800 IU with and without additional 2800 IU vitamin D₃ for osteoporosis: Results from the 24-week extension of a 15-week randomized, controlled trial. *Bone*, 2009, 44, s. 639–647.
 - 50 **Borghi, L. – Schianchi, T. – Meschi, T., et al.:** Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalcaemia. *N Engl J Med*, 2002, 346, s. 77–84.
 - 51 **Curhan, G. C. – Willet, W. C. – Rimm, E. B. – Stampfer, M. J.:** A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. *N Engl J Med*, 1993, 328, s. 833–838.
 - 52 **Jackson, R. D. – La Croix, A. Z. – Gass, M., et al.:** Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. *N Engl J Med*, 2006, 354, s. 669–683.
 - 53 **Heaney, R. P.:** Calcium supplementation and incident kidney stone risk: a systematic review. *J Am Coll Nutr*, 2008, 27, s. 519–527.
 - 54 **Bolland, M. J. – Barber, A. P. – Doughty, R. N., et al.:** Vascular events in healthy older women receiving calcium supplementation: randomized controlled trial. *BMJ*, 2008, 336, s. 262–266.
 - 55 **Bolland, M. J. – Avenell, A. – Baron, J. A., et al.:** Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. *BMJ*, 2010, 341, s. c369.
 - 56 **Pentti, K. – Tuppurainen, M. T. – Honkanen, R., et al.:** Use of calcium supplements and the risk of coronary heart disease in 52–62-year-old women: the Kuopio Osteoporosis Risk Factor and Prevention Study. *Maturitas*, 2009, 63, s. 73–78.
 - 57 **Nordin, B. E. C. – Daly, R. M. – Horowitz, J. – Metcalfe, A. V.:** Making too much of a weak case. *BMJ*, 2010, 341, s. c4997.
 - 58 **Nordin, B. E. C. – Lewis, J. R. – Daly, R. M., et al.:** The calcium scare—what would Austin Bradford Hill have thought? *Osteoporos Int*, 2011, 22, s. 3073–3077.
 - 59 **Burghardt, P.:** Potential negative cardiovascular effects of calcium supplements. *Osteoporos Int*, 2011, 22, s. 1645–1647.
 - 60 **Bolland, M. J. – Grey, A. – Avenell, A. – Gamble, G. D. – Reid, I. R.:** Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. *BMJ*, 2011, 342, s. d2040.
 - 61 **Lewis, J. R. – Calver, J. – Zhu, K. – Flicker, L. – Prince, L. R.:** Calcium supplementation and the risks of atherosclerotic vascular disease in older women: Results of a 5-year RCT and a 4.5-year follow-up. *J Bone Mineral Res*, 2011, 26, s. 35–41.
 - 62 **Michaëlsson, K. – Melhus, H. – Warensjö Lemming, E. – Wolk, A. – Byberg, L.:** Long term calcium intake and rates of all cause and cardiovascular mortality: community based prospective longitudinal cohort study. *BMJ*, 2013, 346, s. f228.
 - 63 **Langsetmo, L. – Berger, C. – Kreiger, N., et al.:** Calcium and vitamin D intake and mortality: Results from the Canadian Multicentre Osteoporosis Study (CaMos). *J Clin Endocrinol Metab*, 2013, doi: 10.1210/jc.2013-1516.
 - 64 **Vieth, R. – Chan, P. – MacFarlane, G.:** Efficacy and safety of vitamin D₃ input exceeding the lowest observed adverse effect concentration. *Am J Clin Nutr*, 2001, 73, s. 288–294.
 - 65 **Nowson, C. – McGrath, J. – Ebeling, P., et al.:** Vitamin D and health in adults in Australia and New Zealand: a position statement. *Med J Aust*, 2012, 196, s. 686–687.
 - 66 **Ross, A. C. – Manson, J. E. – Abrams, S. A., et al.:** The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. *J Clin Endocrinol Metab*, 2011, 96, s. 53–58.
 - 67 **Sanders, K. M. – Nicholson, G. C. – Ebeling, P. R.:** Is high dose vitamin D harmful? *Calcif Tissue Int*, 2013, 92, s. 191–206.
 - 68 **Rizzoli, R. – Boonen, S. – Brandi, M.-L., et al.:** Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). *CMRO*, 2013, 29, s. 1–9.
 - 69 **Bischoff-Ferrari, H. A. – Sbal, A. – Dawson-Hughes, B., et al.:** Benefit-risk assessment of vitamin D supplementation. *Osteoporos Int*, 2010, 21, s. 1121–1132.
 - 70 **Dawson-Hughes, B. – Mithal, A. – Bonjour, J.-P., et al.:** IOF position statement: vitamin D recommendation for older adults. *Osteoporos Int*, 2010, 21, s. 1151–1154.

Vitamin D ve stáří

MUDr. Jana Čepová, Ph.D., MBA | Ing. Eva Klapková, Ph.D. |

Ing. Marta Pechová | Ing. Eliška Glasová | prof. MUDr. Richard Průša, CSc.

Ústav lékařské chemie a klinické biochemie, 2. LF UK a FN v Motole, Praha

- 1 **Mistretta, V. – Delaney, P.:** Vitamin D₂ or Vitamin D₃. *Rev Med Interne*, 2008, 29 (10), s. 815–820.
- 2 Dostupné z: <http://jn.nutrition.org>, vyhledáno 21. 3. 2013.
- 3 **Broulík, P.:** *Osteoporóza*. Maxdorf Jesenius, 1999.
- 4 **Elecsys Bone Marker Testing**, Mannheim, Německo, 2004.
- 5 **Winzenberg, T., et al.:** Vitamin D and the musculoskeletal health of older adults. *Australian Family Physician*, 2012, 41, 3.
- 6 **Čepová, J.:** Vitamin D ve zdraví a nemoci. 13. Bergmeyerova konference. *Labor Aktuell*, 2012, 2.
- 7 **Rosa, J.:** Doporučené postupy pro diagnostiku a terapii postmenopauzální osteoporózy – I. část. *Osteologický bulletin*, 2007.
- 8 **Nair, R. – Maseeh, A.:** Vitamin D: The „sunshine“ vitamin. *Pharmacol Ther*, 2012, 3 (2), s. 118–126.
- 9 **Veselý, O.:** Téma: Vitamin D a křivice či osteomalacie, <http://pfyziol-fup.upol.cz/castwiki2/?p=8255>, vyhledáno 21. 3. 2013.
- 10 **Iliades, Ch.:** Vitamin D deficiency: A common risk factor for seniors, www.parentgiving.com/elder-care/vitamin-d-deficiency-a-common-risk-factor-for-seniors/, vyhledáno 21. 3. 2013.
- 11 **Mercola, M. D.:** This vitamin D supplement mistake raises your death race by 2 %—are you at risk? <http://articles.mercola.com>, vyhledáno 21. 3. 2013.
- 12 **Holick, M. F.:** *The Vitamin D solution*. Hudson Street Press, USA, 2011.
- 13 **Brouwer-Brolsma, E. M. – Bischoff-Ferrari, H. A., et al.:** Vitamin D: do we get enough? *Osteoporosis Int*, 2012, s00198-012-2231-3.

Fixní kombinace v léčbě hypertenze

MUDr. Eva Kociánová I. Interní klinika – kardiologická, Fakultní Nemocnice Olomouc

- 1 Filipovský, J. – Widimský jr., J. – Ceral, J., et al.: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. *Hypertenze & kardiovaskulární prevence*, 2012, 3, s. 1–16.
- 2 Hajjar, I. – Kotchen, T. A.: Trends in prevalence, awareness, treatment, and control of hypertension in the United States 1988-2000. *JAMA*, 2003, 298, s. 199–206.
- 3 Cífková, R. – Bruthans, J. – Adámková, V., et al.: Prevalence základních kardiovaskulárních rizikových faktorů v české populaci v letech 2006–2009. Studie Czech post-MONICA. *Cor Vasa*, 2011, 53, s. 220–229.
- 4 Atreja, A. – Bellam, N. – Levy, S.: Strategies to enhance patient adherence: Making it simple. *Med-scape General Medicine*, 2005, 7 (1), s. 4.
- 5 Hess, G. – Hill, J. – Lau, H., et al.: Medication utilization patterns and hypertension-related expenditures among patients who were switched from fixed-dose to free-combination antihypertensive therapy. *PT*, 2008, 33, s. 652–666.
- 6 Wald, D. S. – Law, M. – Morfia, J. K., et al.: Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. *Am J Med*, 2009, 122 (3), s. 290–300.
- 7 Bangalore, S. – Kamalakkannan, G. – Parkar, S., et al.: Fixed-dose combinations improve medication compliance: a meta-analysis. *Am J Med*, 2007, 120, s. 713–719.
- 8 Corrao, G. – Nicotra, F. – Parodi, A., et al.: Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practise. *Hypertension*, 2011, 58 (5), s. 566–572.
- 9 ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): *Lancet*, 2007, 370, s. 829–840.
- 10 Beckett, N. S. – Peters, R. – Fletcher, A. E., et al.: For the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. *N Engl J Med*, 2008, 358, s. 1887–1898.
- 11 Yamamuro, M. – Yamamoto, K. – Kan, H., et al.: Effects of a fixed combination of losartan with hydrochlorothiazide on glucose tolerance in hypertensive patients uncontrolled with angiotensin II receptor blockers alone. *J Atheroscler Thromb*, 16. 11. 2012.
- 12 Dahlöf, B. – Sever, P. S. – Poulter, N. R., et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomised controlled trial. *Lancet*, 2005, 366, s. 895–906.
- 13 Rothwell, P. – Howard, S. – Dolan, E., et al.: Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. *Lancet*, 2010, 375 (9718), s. 895–905.
- 14 Jamerson, K. – Weber, M. A. – Bakris, G. L., et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med*, 2008, 359, s. 2417–2428.
- 15 Nadar, S. – Lim, H. S. – Beevers, D. G., et al.: Lipid lowering in hypertension and heart protection: observation from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Heart Protection Study. *J Hum Hypertens*, 2002, 16, s. 815–817.
- 16 The ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med*, 2008, 358, s. 1547–1559.
- 17 Malacco, E.: Nebivolol/hydrochlorothiazide (HCTZ) combination in patients with essential hypertension: a pooled analysis from five non-interventional studies with a focus on diabetic and elderly patients. *European Review for Medical and Pharmacological Sciences*, 2010, 14 (5), s. 427–434.
- 18 Marazzi, G. – Volterrani, M. – Caminiti, G., et al.: Effectiveness of nebivolol and hydrochlorothiazide association on blood pressure, glucose, and lipid metabolism in hypertensive patients. *Adv Ther*, 2010, 27 (9), s. 655–664.

Léčba hypertenze v primární péči

MUDr. Zdeněk Hamouz Praktický lékař, SPL ČR, ČIMS, o. p. s.

- 1 Filipovský, J. – Widimský, J. jr. – Ceral, J. – Cífková, R. – Horký, K. – Linhart, A. – Monhart, V. – Rosolová, H. – Seidlerová, J. – Souček, M. – Špinar, J. – Vitovec, J. – Widimský, J.: *Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi: Hypertenze & kardiovaskulární prevence*. 2012, 1, s. 1805–4129.
- 2 Mancia, G. – De Backer, G. – Dominiczak, A., et al.: Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology (ESC). *J Hypertens*, 2007, 25, s. 1105–1187.
- 3 Mancia, G. – Laurent, S. – Agabiti-Rosei, E., et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. *J Hypertens*, 2009, 27, s. 2121–2158.
- 4 *Management of hypertension: summary of NICE guidance BMJ* 2011, 343, doi: <http://dx.doi.org/10.1136/bmj.d4891> (publikováno 25. 8. 2011).
- 5 Lewington, S., et al.: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*, 2002, 360, s. 1903–1913.
- 6 Gu, Q. – Dillon, Ch. F. – Burt, V. L. – Gillum, R. F.: Association of hypertension treatment and control with all-cause and cardiovascular disease mortality among US adults with hypertension. *Am J Hypertens*, 2010, 23, s. 38–45, doi: 10.1038/ajh.2009.191.
- 7 Zavaroni, I. – Mazza, S. – Dall'Aglio, E. – Gasparini, P. – Passeri, M. – Reaven, G. M.: Prevalence of hyperinsulinaemia in patients with high blood pressure. *J Intern Med*, 1992, 231, s. 235–240.
- 8 Lima, N. K. C. – Abbasi, F. – Lamendola, C. – Reaven, G. M.: Prevalence of insulin resistance and related risk factors for cardiovascular disease in patients with essential hypertension. *Am J Hypertens*, 2009, 22, s. 106–111.
- 9 Rosolová, H.: Léčba hypertenze u pacientů s diabetem. *Farmakoterapie*, 2010, s. 420–426.
- 10 Maenhaut, N. – Van de Voorde, J.: Regulation of vascular tone by adipocytes. *BMC Medicine*, 2011, 9, s. 25, <http://www.biomedcentral.com/1741-7015/9/25>.
- 11 UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. *Br Med J*, 1998, 317, s. 713–720.

Akutní infekce dýchacích cest, jejich diagnostika a léčba z pohledu ORL lékaře

MUDr. Petra Bruthansová | MUDr. Pavol Jablonický

Klinika otorinolaryngologie a chirurgie hlavy a krku 1. LF UK a FN Motol, Praha

- 1 **Becker, W.** – **Neumann, H.** – **Pfaltz, C.**: *Ear Nose and Throat diseases*. New York, Thieme Medical Publisher, Inc., 1993.
- 2 **Beneš, J.**: *Infekční lékařství*. Praha, Galén, 2009.
- 3 **Kastner, J.**: Kapesní průvodce EPOS. *Otorinolaryngologie a foniatrie*, 2009, 58, s. 50–62.
- 4 **Klozar, J., et al.**: *Speciální otorinolaryngologie*. Praha, Galén, 2008.
- 5 **Lalwani, A.**: *Current diagnosis & Treatment in Otolaryngology Head and Neck Surgery*. USA, Lange-The McGraw-Hill companies, 2008.
- 6 **Lochmann, O.**: *Základy antimikrobiální terapie*. Praha, Triton, 1999.

Klarithromycin v léčbě atypických pneumonií

MUDr. Jiří Slíva, Ph.D. Ústavy farmakologie 2. a 3. LF UK, Praha

- 1 **Giamarellos-Bourboulis, E. J.**: Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. *Int J Antimicrob Agents*, 2008, 31, s. 12–20.
- 2 **Tateda, K.** – **Standiford, T. J.** – **Pechere, J. C.** – **Yamaguchi, K.**: Regulatory effects of macrolides on bacterial virulence: potential role as quorum-sensing inhibitors. *Curr Pharm Des*, 2004, 10, s. 3055–3065.
- 3 **Sofer, D.** – **Gilboa-Garber, N.** – **Belz, A.** – **Garber, N. C.**: 'Subinhibitory' erythromycin represses production of *Pseudomonas aeruginosa* lectins, autoinducer and virulence factors. *Chemotherapy*, 1999, 45, s. 335–341.
- 4 **Straneo, G.** – **Scarpazza, G.**: Efficacy and safety of clarithromycin versus josamycin in the treatment of hospitalized patients with bacterial pneumonia. *J Int Med Res*, 1990, 18, s. 164–170.
- 5 **Poirier, R.**: Comparative study of clarithromycin and roxithromycin in the treatment of community-acquired pneumonia. *J Antimicrob Chemother*, 1991, 27, s. 109–116.
- 6 **Anderson, G.** – **Esmonde, T. S.** – **Coles, S.** – **Macklin, J.** – **Carnegie, C.**: A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia. *J Antimicrob Chemother*, 1991, 27, s. 117–124.
- 7 **Chien, S. M.** – **Pichotta, P.** – **Siepmann, N.** – **Chan, C. K.**: Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. *Canada-Sweden Clarithromycin-Pneumonia Study Group Chest*, 1993, 103, s. 697–701.
- 8 **Block, S.** – **Hedrick, J.** – **Hammerschlag, M. R.** – **Cassell, G. H.** – **Craft, J. C.**: *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. *Pediatr Infect Dis J*, 1995, 14, s. 471–477.
- 9 **Jang, T. N.** – **Liu, C. Y.** – **Wang, F. D.** – **Yang, S. P.** – **Fung, C. P.**: A randomized comparative study on the safety and efficacy of clarithromycin and erythromycin in treating community-acquired pneumonia. *Zhonghua Yi Xue Za Zhi (Taipei)*, 1995, 55, s. 302–306.
- 10 **Roblin, P. M.** – **Montalban, G.** – **Hammerschlag, M. R.**: Susceptibilities to clarithromycin and erythromycin of isolates of *Chlamydia pneumoniae* from children with pneumonia. *Antimicrob Agents Chemother*, 1994, 38, s. 1588–1589.
- 11 **Hatipoglu, O. N.** – **Tasan, Y.**: A comparative efficacy and safety study of clarithromycin, roxithromycin and erythromycin stearate in mild pneumonia. *Yonsei Med J*, 2000, 41, s. 340–344.
- 12 **O'Doherty, B.** – **Muller, O.**: Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. *Eur J Clin Microbiol Infect Dis*, 1998, 17, s. 828–833.
- 13 **Drehobl, M. A.** – **De Salvo, M. C.** – **Lewis, D. E.** – **Breen, J. D.**: Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. *Chest*, 2005, 128, s. 2230–2237.
- 14 **Mathers, D. L.** – **Hassman, J.** – **Tellier, G.**: Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. *Clin Ther*, 2004, 26, s. 48–62.
- 15 **Tellier, G.** – **Chang, J. R.** – **Asche, C. V.** – **Lavin, B.** – **Stewart, J.** – **Sullivan, S. D.**: Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days. *Curr Med Res Opin*, 2004, 20, s. 739–747.
- 16 **Niederman, M. S.** – **Chang, J. R.** – **Stewart, J.** – **Nusrat, R.** – **Nieman, R. B.**: Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin. *Curr Med Res Opin*, 2004, 20, s. 749–756.
- 17 **Genne, D.** – **Siegrist, H. H.** – **Humair, L.** – **Janin-Jaquat, B.** – **de Torenste, A.**: Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. *Eur J Clin Microbiol Infect Dis*, 1997, 16, s. 783–788.
- 18 **Ramirez, J.** – **Unowsky, J.** – **Talbot, G. H.** – **Zhang, H.** – **Townsend, L.**: Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. *Clin Ther*, 1999, 21, s. 103–117.
- 19 **Moola, S.** – **Hagberg, L.** – **Churchyard, G. A.** – **Dylewski, J. S.** – **Sedani, S.** – **Staley, H.**: A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia. *Chest*, 1999, 116, s. 974–983.
- 20 **Lode, H.** – **Aronkyto, T.** – **Chuchalin, A. G.** – **Jaaskevi, M.** – **Kahnovskii, I.** – **Kleutgens, K.**: A randomised, double-blind, double-dummy comparative study of gatifloxacin with clarithromycin in the treatment of community-acquired pneumonia. *Clin Microbiol Infect*, 2004, 10, s. 403–408.
- 21 **Sokol, W. N., Jr.** – **Sullivan, J. G.** – **Acampora, M. D.** – **Busman, T. A.** – **Notario, G. F.**: A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia. *Clin Ther*, 2002, 24, s. 605–615.
- 22 **Gotfried, M. H.** – **Dattani, D.** – **Riffer, E., et al.**: A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. *Clin Ther*, 2002, 24, s. 736–751.
- 23 **Hoeffken, G.** – **Meyer, H. P.** – **Winter, J.** – **Verhoef, L.**: The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. *Respir Med*, 2001, 95, s. 553–564.

- 24 Giamarellos-Bourboulis, E. J. – Pechere, J. C. – Routsis, C., et al.: Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. *Clin Infect Dis*, 2008, 46, s. 1157–1164.
- 25 Hamedani, P. – Ali, J. – Hafeez, S., et al.: The safety and efficacy of clarithromycin in patients with Legionella pneumonia. *Chest*, 1991, 100, s. 1503–1506.
- 26 Hamada, H. – Kohno, N. – Yokoyama, A. – Kondo, K. – Hiwada, K.: [A case of pneumonia caused by Mycobacterium avium complex successfully treated with clarithromycin]. *Nihon Ronen Igakkai Zasshi*, 2000, 37, s. 749–753.